Ajinomoto Bio-Pharma Services has entered into a manufacturing agreement with Humanigen, Inc., for the fill finish supply of lenzilumab, currently being studied in a Phase III clinical trial in adult, hospitalized patients with COVID-19.
Under the terms of the agreement, Aji Bio-Pharma will provide drug product aseptic fill finish services for Humanigen at its San Diego facility. 
Lenzilumab, Humanigen's proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, is being administered as part of a U.S. multi-center, randomized, placebo-controlled, double-blinded Phase III study for COVID-19 patients. 
Lenzilumab neutralizes GM-CSF, a key cytokine in the initiation of a cytokine storm.
"We are excited to be working with Aji Bio-Pharma for the fill finish production of lenzilumab," said Dr. Cameron Durrant, Chairman and CEO of Humanigen. "This partnership allows us to utilize Aji Bio-Pharma's drug product expertise and infrastructure to provide a timely supply of lenzilumab."

Lenzilumab is currently being studied in a Phase III clinical trial in adult, hospitalized patients with COVID-19.